Eric Curtis Form 3 Aegerion Pharmaceuticals / Eric Curtis ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Curtis Eric

(Last) (First) (Middle)

C/O AEGERION PHARMACEUTICALS, INC.

ONE MAIN STREET, SUITE 800

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/26/2015

3. Issuer Name and Ticker or Trading Symbol
Aegerion Pharmaceuticals, Inc. [ AEGR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
President, U.S. Commercial

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	08/04/2025	Common Stock	40,000	19.52(2)	D
Stock Option (right to buy)	(3)	11/03/2024	Common Stock	65,000	20.93(2)	D

Explanation of Responses:

1. 25% of the shares of common stock underlying this stock option award will vest on August 4, 2016, with the remaining 75% of the shares of common stock underlying this stock option award vesting thereafter in equal monthly installments through August 4, 2019, subject to the Reporting Person's continued employment with the Issuer.

2. The stock option award has an exercise price equal to the closing price of the Issuer's common stock on the NASDAQ Global Select Market on the date of grant.

3. 25% of the shares of common stock underlying this stock option award will vest on November 3, 2015, with the remaining 75% of the shares of common stock underlying this stock option award vesting thereafter in equal monthly installments through November 3, 2018, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

	/s/ Jennifer Fitzpatrick, attorney-in-fact	09/04/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.